Description of Medical Areas
About the FDA Approved Listings
|
 |
Drugs Approved by the FDA (2005)
|
The following drugs have been approved this year by
the Food and Drug Administration.
Cardiology/Vascular Diseases
|
|
Dental/Maxillofacial Surgery
|
|
Dermatology/Plastic Surgery
|
|
Byetta (exenatide); For the adjunctive treatment of Type 2 diabetes mellitus; Amylin/Eli Lilly; Approved April, 2005 Increlex (mecasermin); For the treatment of growth failure due to Primary IGFD; Tercica; Approved August 2005 Symlin (pramlintide); For the treatment of type I and type II diabetes; Amylin Pharmaceuticals; Approved March 2005
Revlimid (lenalidomide); For the treatment of low- and intermediate-1-risk myelodysplastic syndromes; Celgene; Approved December 2005
Immunology/Infectious Diseases
|
|
Aptivus (tipranavir); For the adjunctive treatment of HIV-1 infections; Boehringer Ingelheim; Approved June, 2005 Baraclude (entecavir); For the treatment of chronic hepatitis B infections with evidence of active viral replication; Bristol-Myers Squibb; Approved March, 2005
Boniva (ibandronate); For the treatment and prevention of osteoporosis; Roche / GlaxoSmithKline; Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005 Naglazyme (galsulfase); For the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome); BioMarin Pharmaceuticals; Approved May 2005
TYSABRI (natalizumab); For the treatment of relapsing forms of multiple sclerosis; Elan Pharmaceuticals / Biogen Idec; Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA
Arranon (nelarabine); For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma; GlaxoSmithKline; Approved October 2005 Nexavar (sorafenib); For the Treatment of Renal Cell Carcinoma; Bayer/Onyx; Approved December 2005
Pulmonary/Respiratory Diseases
|
|
Orencia (abatacept); For the Treatment of Rheumatoid Arthritis; Bristol-Myers Squibb; Approved December 2005
Trauma/Emergency Medicine
|
|
|
|
Back to Centerwatch Drug Directories
|
